PDS >> Efficacy Models >> Respiratory

Respiratory In Vivo Models for Drug Discovery


Respiratory diseases affect the upper respiratory tract and can result in difficulty breathing, decreased lung capacity, asthma, emphysema and a host of other conditions.  Left untreated, respiratory diseases can result in chronic breathing issues and become potentially life threatening.

For over 30 years, Pharmacology Discovery Services has recognized the need for effective and relevant in vivo models for respiratory conditions.  In order to help you bring the next potential respiratory treatment to clinical trials, we offer a number of relevant validated models to help you understand the effectiveness of your test agent.  All Respiratory in vivo models are validated in a dose-dependent manner with approved benchmark positive controls to assure high-quality, reproducible data is provided to our clients.  To meet the needs of your specific Respiratory drug discovery project we also have the flexibility and expertise to develop custom in vivo models.

Speak with
an expert

Download our
model list



Validated Respiratory In Vivo Models

To help you advance your respiratory treatment in drug discovery, we offer a number of relevant qualified models that include:

  • Pulmonary Inflammation
  • Allergic Reaction
  • Airway Hypersensitivity
  • Antagonism of Pro-inflammatory Mediators
  • Bacterial Pneumonia
  • Cough Suppression
  • LPD Induced Neutrophilia

Routine Outcome Measures

Our laboratory staff routinely provides outcome measures of relevant markers that include:

  • Blood Gases
  • Cytokine Detection in Plasma or Bronchoalveolar Lavage Fluid
  • Respiration Rate
  • Respiratory Mechanics
  • Tidal Volume
  • Minute volume employing whole body plethysmography
  • Detailed analysis of respiratory mechanics

In Vivo Pharmacology Expertise

Each of our Technical Directors specializes in selected therapeutic areas so they may provide expert scientific support to our clients.  This involves consulting with clients to identify an appropriate model to meet their scientific objectives, designing studies and writing the custom protocols and statements of work (SOWs) to meet quality assurance guidelines.  They also work closely with our Study Directors to assure that SOWs are clear and that all methods and timelines are feasible.  Our laboratory staff also averages 15 years of experience conducting in vivo pharmacology studies. 

Respiratory Models
Model Name Item Number Species Price/Animal ($USD)
Acinetobacter baumannii (ATCC 17978), Lung Infection Model, CFU/g 608800 Mouse 260
Acinetobacter baumannii Carbapenem resistant ADC-25 OXA-23 OXA-66 (FDA-CDC AR-BANK#0282) Lung Infection Model 608820 Mouse 260
Asthma, Airway Hyperresponsiveness (AHR), Ovalbumin-Induced 568050 Mouse 590
Cough, Capsaicin-Induced 508850 Guinea Pig 420
Cough, Citric Acid-Induced 508800 Guinea Pig 450
Fibrosis, Lung, Bleomycin-Induced 568070 Mouse 375
Klebsiella pneumoniae (ATCC 43816), Lung Infection Model, CFU/g 608550 Mouse 260
Klebsiella pneumoniae NDM-1 (NCTC 13443), Lung Infection Model, CFU/g 608574 Mouse 260
Klebsiella pneumoniae, Carbapenem resistant KPC-2 (BAA 1705), Lung Infection Model, CFU/g 608572 Mouse 260
Pseudomonas aeruginosa (ATCC 27853), Lung Infection Model, CFU/g 608640 Mouse 260
Pseudomonas aeruginosa Carbapenem Resistant (FDA-CDC AR-BANK#0094), Lung Infection Model, CFU/g 608643 Mouse 260
Pseudomonas aeruginosa Carbapenem Resistant (FDA-CDC AR-BANK#0264), Lung Infection Model, CFU/g 608649 Mouse 260
Pseudomonas aeruginosa Carbapenem Resistant (LES 431), Lung Infection Model 608645 Mouse 260
Pseudomonas aeruginosa IMP-1 (FDA-CDC AR-BANK#0103), Lung Infection Model, CFU/g 608644 Mouse 260
Pseudomonas aeruginosa OXA-2 OXA-50 (FDA-CDC AR-BANK#0105), Lung Infection Model, CFU/g 608646 Mouse 260
Pseudomonas aeruginosa SPM-1 (FDA-CDC AR-BANK#0064), Lung Infection Model, CFU/g 608642 Mouse 260
Pseudomonas aeruginosa VIM-2 (FDA-CDC AR-BANK#0108), Lung Infection Model, CFU/g 608647 Mouse 260
Pseudomonas aeruginosa VIM-4 (FDA-CDC AR-BANK#0054), Lung Infection Model, CFU/g 608641 Mouse 260
Pulmonary, Lipopolysaccharide-Induced Neutrophilia, Mouse 572100 Mouse 210
Pulmonary, Lipopolysaccharide-Induced Neutrophilia, Rat 572110 Rat 270
Respiration, Blood Gases 576650 Rat 480
Respiration, Rate, Tidal Volume, Minute Volume and Blood Gases 576660 Rat 505
Staphylococcus aureus MRSA (ATCC 33591), Lung Infection Model, CFU/g 608125 Mouse 260
Streptococcus pneumoniae (ATCC 6301), Lung Infection Model, LD90-100 608100 Mouse 180
Streptococcus pneumoniae (ATCC 6303), Lung Infection Model, CFU/g 608095 Mouse 260